May & Baker Nigeria Plc has swung back to profit in the final quarter of 2025, with revenue rising to 8.74 billion naira from 7.08 billion naira a year earlier.
The pharmaceutical company posted a net profit of 1.12 billion naira, reversing a loss of 114.6 million naira in the same period of 2024.
For the full year, revenue reached 38.26 billion naira, up from 28.91 billion naira in 2024, while net profit increased to 4.46 billion naira from 1.62 billion naira.
The company’s basic earnings per share stood at 2.58 naira, nearly triple the prior year level.
The T.Y. Danjuma family, through investment vehicle T.Y. Holdings, maintains a controlling stake of 41.78%. Samuel Onyishi Maduka is another substantial shareholder with 15.45%.
May & Baker’s performance comes as Nigerian companies navigate a challenging economic environment, with many reporting strong top-line growth despite a weaker currency and higher borrowing costs.
May & Baker is a longtime name in Nigeria’s pharmaceutical market, producing medicines and vaccines and selling a small amount of packaged water under the Lily brand.
The company’s latest numbers cap a year of resilience in the face of economic headwinds.
The pharmaceutical sector in Nigeria has seen significant growth in recent years, driven by increasing demand for healthcare products and services.
May & Baker’s return to profit is a testament to the company’s strong market position and ability to adapt to changing economic conditions.
